Naquotinib

CAS No. 1448232-80-1

Naquotinib ( ASP8273 )

Catalog No. M11913 CAS No. 1448232-80-1

Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 55 Get Quote
5MG 88 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Naquotinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.
  • Description
    Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR (IC50=8-33 nM for (L858R, exon 19 deletion, L858R/T790M, and del19/T790M)); more potently than that of WT EGFR (IC50= 230 nM); shows activity in mutant EGFR cell line which is resistant to other EGFR TKIs including AZD9291 and CO-1686.Lung Cancer Phase 1 Discontinued
  • Synonyms
    ASP8273
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    Cancer
  • Indication
    Lung Cancer

Chemical Information

  • CAS Number
    1448232-80-1
  • Formula Weight
    562.71
  • Molecular Formula
    C30H42N8O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO
  • SMILES
    CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC5CCN(C5)C(=O)C=C
  • Chemical Name
    2-Pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3R)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Wang S, et al. J Hematol Oncol. 2016 Apr 12;9:34.
molnova catalog
related products
  • AZD-9291 dimesylate

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.

  • Afatinib

    Afatinib is an orally bioavailable anilino-quinazoline derivative and inhibitor of the receptor tyrosine kinase (RTK) epidermal growth factor receptor (ErbB; EGFR) family, with antineoplastic activity.

  • Withanolide A

    Withanolide A extends the lifespan in human EGFR-driven cancerous Caenorhabditis elegans.